Cargando…
Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607363/ https://www.ncbi.nlm.nih.gov/pubmed/35006462 http://dx.doi.org/10.1186/s43556-021-00042-3 |
| _version_ | 1784602550185492480 |
|---|---|
| author | Wang, Yuxun Yang, Heping Li, Huanping Zhao, Shuda Zeng, Yikun Zhang, Panpan Lin, Xiaoqin Sun, Xiaoxiang Wang, Longsheng Fu, Guangliang Gao, Yaqiao Wang, Pei Gao, Daxin |
| author_facet | Wang, Yuxun Yang, Heping Li, Huanping Zhao, Shuda Zeng, Yikun Zhang, Panpan Lin, Xiaoqin Sun, Xiaoxiang Wang, Longsheng Fu, Guangliang Gao, Yaqiao Wang, Pei Gao, Daxin |
| author_sort | Wang, Yuxun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8607363 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86073632021-12-01 Correction to: Development of a novel TLR8 agonist for cancer immunotherapy Wang, Yuxun Yang, Heping Li, Huanping Zhao, Shuda Zeng, Yikun Zhang, Panpan Lin, Xiaoqin Sun, Xiaoxiang Wang, Longsheng Fu, Guangliang Gao, Yaqiao Wang, Pei Gao, Daxin Mol Biomed Correction Springer Singapore 2021-05-21 /pmc/articles/PMC8607363/ /pubmed/35006462 http://dx.doi.org/10.1186/s43556-021-00042-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Wang, Yuxun Yang, Heping Li, Huanping Zhao, Shuda Zeng, Yikun Zhang, Panpan Lin, Xiaoqin Sun, Xiaoxiang Wang, Longsheng Fu, Guangliang Gao, Yaqiao Wang, Pei Gao, Daxin Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title | Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title_full | Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title_fullStr | Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title_full_unstemmed | Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title_short | Correction to: Development of a novel TLR8 agonist for cancer immunotherapy |
| title_sort | correction to: development of a novel tlr8 agonist for cancer immunotherapy |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607363/ https://www.ncbi.nlm.nih.gov/pubmed/35006462 http://dx.doi.org/10.1186/s43556-021-00042-3 |
| work_keys_str_mv | AT wangyuxun correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT yangheping correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT lihuanping correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT zhaoshuda correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT zengyikun correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT zhangpanpan correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT linxiaoqin correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT sunxiaoxiang correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT wanglongsheng correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT fuguangliang correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT gaoyaqiao correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT wangpei correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy AT gaodaxin correctiontodevelopmentofanoveltlr8agonistforcancerimmunotherapy |